Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.33 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16750986 | 0.94 | GRIN1 (0.36) | GRIN1GRIN2AGRIN2BOTUD7BSOS1 | |
| SCHEMBL16751010 | 0.86 | GRIN1 (0.38) | GRIN1GRIN2AGRIN2BOTUD7BSOS1 | |
| SCHEMBL17608866 | 0.83 | HSD17B10 (0.41) | GRIN1GRIN2AGRIN2BOTUD7BSOS1 | |
| SCHEMBL12121672 | 0.79 | OTUD7B (0.34) | GRIN1GRIN2AGRIN2BOTUD7BSOS1 | |
| SCHEMBL19329547 | 0.78 | HSD17B10 (0.44) | OTUD7BSOS1SOS2HSD17B10 | |
| SCHEMBL18800970 | 0.78 | SLC6A9 (0.38) | OPRM1OPRL1SLC6A9HSD17B10 | |
| SCHEMBL19852916 | 0.78 | GRIN1 (0.34) | GRIN1GRIN2AGRIN2BOTUD7B | |
| SCHEMBL12028851 | 0.76 | SLC6A9 (0.34) | SOS1SOS2OPRM1OPRL1SLC6A9 | |
| SCHEMBL23556729 | 0.76 | SOS1 (0.44) | GRIN1GRIN2AGRIN2BOTUD7BSOS1 | |
| SCHEMBL19852849 | 0.75 | HSD11B1 (0.44) | GRIN1GRIN2AGRIN2BOTUD7BOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524940-B1 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | GRIN1 4507/4885GRIN2A 4676/4885GRIN2B 4555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.